Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 2017 Aug 22;1(19):1533-1536
Date
01/04/2018Pubmed ID
29296794Pubmed Central ID
PMC5728466DOI
10.1182/bloodadvances.2017007526Scopus ID
2-s2.0-85040141428 (requires institutional sign-in at Scopus site) 122 CitationsAbstract
Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.
Author List
Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D, Talano JAuthors
Larisa Broglie MS, MD Associate Professor in the Pediatrics department at Medical College of WisconsinDavid A. Margolis BA, MD Chair, Professor in the Pediatrics department at Medical College of Wisconsin
Rachel A. Phelan MPH, MD Professor in the Pediatrics department at Medical College of Wisconsin
Sid Rao PhD, MD Associate Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
